Menu Search
Equities

Dexcom Inc

DC4:DUS

Dexcom Inc

Actions
  • Price (EUR)65.60
  • Today's Change2.17 / 3.42%
  • Shares traded30.00
  • 1 Year change-23.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.

  • Revenue in USD (TTM)3.95bn
  • Net income in USD680.80m
  • Incorporated1999
  • Employees9.60k
  • Location
    Dexcom Inc6340 Sequence DrSAN DIEGO 92121-4356United StatesUSA
  • Phone+1 (858) 200-0200
  • Fax+1 (302) 636-5454
  • Websitehttps://www.dexcom.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.